Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) Shares Outstanding (Weighted Average) (2018 - 2024)

Historic Shares Outstanding (Weighted Average) for TransMedics (TMDX) over the last 7 years, with Q3 2024 value amounting to $33.4 million.

  • TransMedics' Shares Outstanding (Weighted Average) rose 253.67% to $33.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $33.4 million, marking a year-over-year increase of 253.67%. This contributed to the annual value of $32.5 million for FY2023, which is 1001.72% up from last year.
  • Per TransMedics' latest filing, its Shares Outstanding (Weighted Average) stood at $33.4 million for Q3 2024, which was up 253.67% from $33.1 million recorded in Q2 2024.
  • TransMedics' 5-year Shares Outstanding (Weighted Average) high stood at $33.4 million for Q3 2024, and its period low was $21.2 million during Q1 2020.
  • For the 5-year period, TransMedics' Shares Outstanding (Weighted Average) averaged around $29.0 million, with its median value being $28.0 million (2022).
  • Per our database at Business Quant, TransMedics' Shares Outstanding (Weighted Average) soared by 139619.91% in 2020 and then surged by 131.37% in 2022.
  • TransMedics' Shares Outstanding (Weighted Average) (Quarter) stood at $24.7 million in 2020, then grew by 11.8% to $27.6 million in 2021, then grew by 7.02% to $29.6 million in 2022, then grew by 10.02% to $32.5 million in 2023, then increased by 2.84% to $33.4 million in 2024.
  • Its Shares Outstanding (Weighted Average) stands at $33.4 million for Q3 2024, versus $33.1 million for Q2 2024 and $32.8 million for Q1 2024.